a 1st Chair and Department of Oncological Gynaecology and Gynaecology, Tumor Immunology Laboratory , Medical University of Lublin , Lublin , Poland.
b Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland.
Crit Rev Clin Lab Sci. 2018 Sep;55(6):376-407. doi: 10.1080/10408363.2018.1477729. Epub 2018 Jun 21.
Progress in cancer treatment made by the beginning of the 21st century has shifted the paradigm from one-size-fits-all to tailor-made treatment. The popular vision, to study solid tumors through the relatively noninvasive sampling of blood, is one of the most thrilling and rapidly advancing fields in global cancer diagnostics. From this perspective, immune-cell analysis in cancer could play a pivotal role in oncology practice. This approach is driven both by rapid technological developments, including the analysis of circulating myeloid-derived suppressor cells (cMDSCs), and by the increasing application of (immune) therapies, the success or failure of which may depend on effective and timely measurements of relevant biomarkers. Although the implementation of these powerful noninvasive diagnostic capabilities in guiding precision cancer treatment is poised to change the ways in which we select and monitor cancer therapy, challenges remain. Here, we discuss the challenges associated with the analysis and clinical aspects of cMDSCs and assess whether the problems in implementing tumor-evolution monitoring as a global tool in personalized oncology can be overcome.
21 世纪初癌症治疗的进展已经将范式从一刀切转变为量身定制的治疗。通过相对无创的血液取样来研究实体肿瘤，这一流行观点是全球癌症诊断学中最令人兴奋和迅速发展的领域之一。从这个角度来看，癌症中的免疫细胞分析可能在肿瘤学实践中发挥关键作用。这种方法不仅受到快速技术发展的推动，包括循环髓系来源抑制细胞（cMDSCs）的分析，还受到（免疫）疗法应用的增加的推动，其成败可能取决于对相关生物标志物的有效和及时测量。尽管这些强大的无创诊断能力在指导精准癌症治疗中的实施有望改变我们选择和监测癌症治疗的方式，但挑战依然存在。在这里，我们讨论了与 cMDSCs 分析和临床方面相关的挑战，并评估了将肿瘤进化监测作为个性化肿瘤学中的全球工具实施所面临的问题是否可以克服。
